07.03.25 -- Late-Stage Formulation Is A Different Ballgame. Insights From An Allstar

20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We're confident you don’t need 20/20 vision to see the value in this! Join us for Outsourced Pharma's July Partner Week – including sessions in Small Molecule API/HPAPI, Small Molecule Finished Dosage Form, ADC, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free.

Review the analytical considerations for subunit vaccines, vaccines that contain only the antigenic component(s) of a pathogen, and the assays needed.

Discover key factors that drive a seamless and efficient technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success in the CDMO industry.

Explore how the right system can be tailored to meet the needs of each unique biologic. Whether trying to achieve speed and cost-effectiveness, higher yields, and glycosylation capabilities.

The FDA's vouchers will be issued to companies addressing health issues in the U.S. and increasing domestic manufacturing, among other criteria.

Learn why partnering with a leader in outsourced stability storage is revolutionizing the pharmaceutical and medical device industry by saving costs and resources, and ensuring product quality.

Adopt principles in your biologics development and manufacturing process to ensure consistent product quality, mitigate risks, and align with patient safety and commercial success goals.

Witness how our capabilities in phage and yeast surface display can drive your next protein engineering or therapeutic antibody development project forward.

Blending pharmaceuticals and medical devices into a single product offers immense potential for patient care, but manufacturing these combination products presents unique hurdles.

Delve into the challenges of scaling in drug development through insights from both biopharma developers and a CDMO, and their shared goal of a successful scale-up.

A comprehensive Risk Analysis and Control Strategy is built on key pillars, each playing a vital role in ensuring that every final product meets the highest standards of safety and efficacy.

Accelerated timelines offer developers a pathway to rapidly bring new therapies to market while maintaining a balance of risk and benefit assessment. 

Early collaboration with a clinical supply manager can help proactively negotiate potential pitfalls. Observe efficient resupply practices and execute successful supply chain strategies.

Microbial fermentation has experienced a renaissance in recent years. Examine the benefits of microbial fermentation for biologics production and improvements introduced to a microbial expression platform.

Biosafety testing ensures biologics' safety and quality but faces challenges like cost, time, and technical complexity. Proper planning and regulatory compliance are key to success.

Observe how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.

With extensive experience, we deliver scalable, high-quality solutions tailored to challenging molecular constructs, ensuring efficiency and safety in the production of therapeutic modalities.

We've expanded our U.S. and Germany sites to offer end-to-end services for product development, clinical and commercial fill/finish, and ADC conjugation and purification by 2025.

Drawing on over 30 years of experience in biological processing, we offer our customers a comprehensive service package spanning all stages of development and production.